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ABSTRACT In this article, we introduce and apply our de novo protein design framework, which observes true backbone ﬂexi-
bility, to the redesign of human b-defensin-2, a 41-residue cationic antimicrobial peptide of the innate immune system. The ﬂexible
design templates are generated using molecular dynamics simulations with both Generalized Born implicit solvation and explicit
water molecules. These backbone templates were employed in addition to the x-ray crystal structure for designing human
b-defensin-2. The computational efﬁciency of our framework was demonstrated with the full-sequence design of the peptide with
ﬂexible backbone templates, corresponding to the mutation of all positions except the native cysteines.
INTRODUCTION
Recently there has been growing attention to the importance
of antimicrobial peptides (AmPs), which are small proteins
of fewer than 100 amino acids that are found in the innate
immune system as defense against bacterial infection. This
is evidenced by the publication of several important re-
views and articles about AmPs (1–6). One of the main
reasons is believed to be the better capability of AmPs to
combat bacterial resistance compared to conventional anti-
biotics (3,7).
The various families of AmPs that have been identiﬁed in
humans so far include histatins, granulysin, lactoferricin, de-
fensins, and cathelicidins, with a- and b-defensins being the
most common AmPs (8). The a- and b-defensin classes differ
by the positions and connectivity of their six native cysteine
residues (9). Human a-defensins, HNP-1 to -4, are found in
the storage granules of neutrophils for the killing of ingested
microorganisms (10). On the other hand, human b-defensins
are expressed in the salivary glands (11,12), the skin (13), and
the epithelial tissues (14,15). Six human b-defensins (hbD-1
to -6) have been identiﬁed thus far (8,16), and in this research
article we focus on humanb-defensin-2 (hbD-2) and its de novo
computational design using our novel framework (17–20).
The cationic 41-residue peptide hbD-2 was ﬁrst discov-
ered in 1997 in the human skin (13). It has one a-helix, a
b-sheet made of three b-strands, and three disulﬁde bonds
between Cys8 and Cys37; Cys15 and Cys30; and Cys20, and
Cys38, respectively. Since its discovery, it has been shown to
be a potent AmP effective against a large variety of
microbes, including both Gram-negative bacteria and fungi
(21,22). Its antimicrobial property is partly attributed to its
high positive charge (16) which provides a strong electro-
static force between the peptide and the negatively charged
outermost leaﬂet of the microbial membrane bilayer. Based
on the Shai-Matsuzaki-Huang mechanism (23–25) by which
most other AmPs function, the electrostatic force drives the
interaction of the molecule with the membrane, alters the
membrane structure, and sometimes even leads to the entry
of the peptide into the interior of the microorganism. In
addition, hbD-2 serves as a chemotactic agent for T-cells,
immature dentritic cells, mast cells, and tumor necrosis
factor-a-treated neutrophils (8,26,27). Most importantly, it
suppresses the oral transmission of HIV-1, the mechanism of
which is still poorly understood, at doses that are compatible
with those in the oral cavity (28,29). These characteristics
make hbD-2 an ideal candidate as an antimicrobial gene
therapy study model (30) and a new generation antibiotic.
Computational de novo design approaches use either rigid
templates or ﬂexible templates (31,32). In the former case,
the sequence search method is driven either by deterministic
methods like the dead-end elimination (33–38) and the self-
consistent mean ﬁeld method (39–41), or by stochastic
methods like Monte Carlo methods (42–44) and genetic
algorithms (45) based on a single ﬁxed backbone. In the case
of ﬂexible templates, de novo design was performed using
the same search methods by considering discrete rotamers on
discrete templates with ﬁxed backbone assumption for each
template (41,46–54), or considering discrete rotamers on a
continuum template via backbone parameterization (55–57).
Our recently proposed de novo design strategy also em-
ployed ﬂexible templates, but via a continuum template and
NMR structure reﬁnement instead of discrete rotamers, so
that all continuous Ca-Ca distance and dihedral angle values
between preset upper and lower bounds are considered
(19,20,58). With the study of human b-defensin-2, we aim at
illustrating how our framework can be applied to the full-
sequence de novo design of proteins.
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The objective of the de novo design of hbD-2 is to enhance
the peptide’s antimicrobial property. Krishnakumari et al. (59)
investigated the antibacterial activity of a synthetic 19-residue
peptide corresponding with position 19 to position 39 of hbD-2
without Cys30 and Cys37. Loose et al. (6) designed new AmPs
against Escherichia coli, Bacillus anthracis, and Staphylo-
coccus aureus using a purely linguistic approach and ob-
tained favorable experimental results. In our de novo design,
instead of ﬁxing the carboxy-terminal region as Krishnaku-
mari et al. (59) did, we considered two separate cases:
1. Up to 10 mutations along hbD-2.
2. Full-sequence design of hbD-2 by mutating all positions
except Cys8, Cys15, Cys20, Cys30, Cys37, and Cys38, so as
to keep the original S-S bridge architecture and thus the
overall structure of the peptide.
Unlike Loose et al. (6)’s approach, we employed the
structures of hbD-2 as design templates and identiﬁed se-
quences of new peptides that have the lowest potential ener-
gies and thus highest speciﬁcities to the templates. Ideally,
we should have used the structures of the microbial membrane-
peptide complex as design templates. However, they are not
readily available in the open literature and are hard to predict
with high accuracy. Therefore, we resorted to minimizing the
potential energy of the peptide only. Such a strategy has
proven to be highly successful in the design of compstatin, a
synthetic 13-residue cyclic peptide that binds to complement
protein 3 (C3) and inhibits the activation of the complement
system, in which the design template was conﬁned to
compstatin only (17,18). In this de novo design of hbD-2,
in addition to the crystal structure of hbD-2 elucidated by
Hoover et al. (60), we generated ﬂexible templates using
molecular dynamics simulations with implicit solvation and
explicit water molecules and used them as design templates
so as to allow for true backbone ﬂexibility.
In this article, our new de novo protein design methodol-
ogy will be presented ﬁrst. It will be followed by the study of
its application to the design of hbD-2. Finally, we will
present the predictions corresponding to the different set of
backbone templates employed.
A new de novo protein design framework
In this article, a novel two-stage framework is introduced and
applied to the de novo design of human b-defensin-2. The
ﬁrst stage selects amino-acid sequences into either a single
template or multiple templates deﬁned by either the Ca
positions or the side-chain centroids in the template(s). As
proven by Pierce and Winfree (61) and by Fung et al. (19),
this is an NP-hard problem. The second stage calculates and
ranks the fold speciﬁcities of the sequences selected in the
ﬁrst stage based on the full-atomistic force ﬁeld AMBER
(62), and torsional angle dynamics with restraints through
CYANA (63,64).
Stage one: in silico sequence selection
Sequence selection based on a single template structure
The basic sequence selection model for single template struc-
ture, recently proposed by Fung et al. (20), has the mathe-
matical formulation of
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and it is an integer linear programming model. Set i¼ 1, . . . , n
deﬁnes the number of residue positions along the template.
At each position i there can be a set of mutations represented
by jfig ¼ 1, . . . , mi, where, for the general case, mi ¼ 20"i.
The equivalent sets k [ i and l [ j are deﬁned, and k . i is
required to represent all unique pairwise interactions. Binary
variables yji and y
l
k are introduced to indicate the possible
mutations at a given position. That is, the yji variable will
indicate which type of amino acid is active at a position in the
sequence by taking the value of 1 for that speciﬁcation. The
composition constraints in the formulation require that there
is exactly one type of amino acid at each position. Noting
that binary variable wjlik is simply the product of y
j
i and y
l
k; the
RLT constraints, namely +mi
j¼1w
jl
ik ¼ ylk " i; k. i; l and
+mk
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jl
ik ¼ yji " i; k. i; j; can be derived by multiplying the
composition constraints +mi
j¼1y
j
i ¼ 1" i by ylk and
+mk
l¼1y
l
k ¼ 1" k. i by yji; respectively.
The objective function to be minimized represents the sum
of pairwise amino-acid energy interactions in the template.
Parameter Ejlikðxi; xkÞ; which is the energy interaction be-
tween position i occupied by amino acid j and position k
occupied by amino acid l, depends on the distance between
the a-carbons or side-chain centroids at the two positions (xi,
xk) as well as the type of amino acids j and l. These energy
parameters were derived based on solving a linear program-
ming parameter estimation problem subject to constraints
which were in turn constructed by requiring the energies of a
large number of low-energy decoys to be larger than the
corresponding native protein conformation for each member
of a set of proteins (65). The resulting potential, which
contains 1680 energy parameters for different amino-acid
pairs and distance bins, was shown to rank the native fold
as the lowest in energy in a large set of proteins tested and
also yield very good Z-scores (65–67).
Equation 1 was proved to be signiﬁcantly more com-
putationally efﬁcient than 12 other equivalent quadratic
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assignments like models for sequence selection (19,20). In
particular, it outperformed the original model proposed by
Klepeis et al. (17) on two sequence selection problems for
human b-defensin-2: one at a complexity level of 3.4 3
1045, and the other at 6.4 3 1037 with 49 additional linear
biological constraints. The original model proposed by
Klepeis et al. (17) was found to take 53,263 CPU seconds
and 4578 CPU seconds, respectively, to solve the two
problems to global optimality using CPLEX 9.0 (68) on a
Pentium IV 3.2 GHz processor. Equation 1 only took 649
CPU seconds and 14 CPU seconds to perform the same
tasks, corresponding to an 82-fold and 327-fold improve-
ment in computational efﬁciency.
Sequence selection based on multiple
template structures
In an effort to handle the typical case of de novo protein design
in which the design template possesses multiple crystal or
NMR solution structures, Fung et al. (20) proposed two new
sequence selection formulations. One uses a weighted aver-
age force ﬁeld in place of the energy parameters in the single
structure model (Eq. 1), with the weights given by the oc-
currence frequencies of each Ca-Ca or centroid-centroid
distance belonging to a certain distance bin as observed from
the template structures. With the aid of binary variables, the
other formulation allows the inclusion of all distance bins that
each Ca-Ca or centroid-centroid distance covers according to
the template structures. It also imposes constraints that
disallow the selection of distance bin combinations which
suggest physically meaningless results.
Weighted average force ﬁeld formulation
In the case when there is only one structure, the energy
parameter Ejlikðxi; xkÞ in the objective function can be imme-
diately determined by the coordinates of the two Ca or side-
chain centroid positions, that is, xi and xk, as well as the
amino acid at each of those two positions. There is no am-
biguity as to which distance bin d it belongs to. In the case of
multiple structures, the term Ejlikðxi; xkÞ can be replaced by
a weighted average energy term,+bm
d¼1E
jl
ikðxi; xkÞwtðxi; xk; dÞ;
where the weights wt(xi, xk, d) are given by
The idea can also be examined this way: the distance between
xi and xk is now replaced by a weighted average distance over
all the structures, with the weights given by the above formula.
The energy parameters Ejlikðxi; xkÞ can be found using this
weighted average distance and simple table lookup in the
corresponding force ﬁeld. With all components other than the
energy term kept, the new formulation becomes
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Equation 3 is an integer linear programming model.
Binary distance bin variable formulation
This new formulation was derived by ﬁrst replacing the
energy parameter Ejlikðxi; xkÞ in the objective function of Eq. 1
by +
d:disbinðxi;xk;dÞ¼1E
jl
ikðxi; xkÞbikd; where bikd is a binary
variable which assumes the value of one if the distance
between xi and xk falls into distance bin d and the value of
zero otherwise, and disbin(xi, xk, d) is a parameter deﬁned as
disbin(xi, xk, d)
¼ 1 if the distance between xi and xk in any of the
template structures falls into bin d;
¼ 0 otherwise " i, k . i, d.
The constraints of +
d:disbinðxi;xk;dÞ¼1bikd ¼ 1"i; k.i were
imposed to let the energy minimization model pick only one
of the distance bins that all the structures cover. After re-
placing the energy term, the model takes the form
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Equation 4 is nonconvex because of the bilinear term bikdw
jl
ik
in the objective function. Fung et al. (20) linearized the
formulation by declaring zjlikd ¼ bikdwjlik as binary variables
and using the RLT equations:
wtðxi; xk; dÞ ¼ number of structures inwhich distance between xi and xk is in bin d
total number of structures of the template
" i; k; d: (2)
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Moreover, Fung et al. (20) also derived novel constraints on
the binary distance bin variables to eliminate results in which
there is no overlap between regions where the same Ca or
side-chain centroid position can possibly be located:
bikd1bkpd9#1
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lmidðd9Þ.disði;pÞ1 lmidðdÞÞ
and
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Without these constraints, the design template deﬁned only
by Ca or side-chain centroid positions would be given too
much ﬂexibility.
With the linearization components and these new con-
straints on distance bin variables, the whole model for se-
quence selection into multiple templates takes the form of
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The high resolution force ﬁelds for
sequence selection
In thiswork, the high resolutionCa-Ca force ﬁeld and the high
resolution centroid-centroid force ﬁeld were employed for
addressing the sequence selection models (69,70). These
force ﬁelds are derived from a large training set of 1250
proteins based on high resolution decoys. The force ﬁelds are
obtained by solving a linear programming parameter estima-
tion problem, requiring that the native conformation of each
protein in the training set to be ranked energetically more
favorable than their decoys. By using a novel decoy gener-
ation method, Rajgaria et al. (69) constructed high resolution
decoys which possessed close structural resemblance to the
native conformations, and these decoys were subsequently
used for training the force ﬁelds.
Backbone ﬂexibility at stage one
True backbone ﬂexibility, deﬁned by bounded continuous
values of dihedral angles and Ca-Ca distances (71), is
explicitly incorporated into Eqs. 1, 3, and 7 for sequence
selection. In all models it is achieved by discretizing the
Ca-Ca or centroid-centroid distance-dependent energy po-
tential Ejlikðxi; xkÞ into a number of bins based on the distance
between the two positions (xi, xk). For example, in the high
resolution Ca-Ca force ﬁeld developed by Rajgaria et al. (69),
if the pair of amino acids selected at positions i and k are Arg
and Glu, respectively, and the corresponding a-carbons are
3.5 A˚ apart in a single template structure or a weighted
average template, their energy contribution to the objective
functionwill be7.77 kcal/mol. This energy value is constant
for all Arg and Glu residues with a Ca-Ca distance between 3
and 4 A˚ (bin 1), thusmaking the objective function insensitive
to limited continuous distance variation due to protein
backbone motion. A higher degree of backbone ﬂexibility is
included in the binary distance bin variable formulation than
in other models, because the whole distance range for each
position pair (xi, xk) spanned by all structures is considered.
For instance, if the distance between the same selected amino
acid pair Arg-Glu at positions i and k covers bin 1 (3–4 A˚ with
energy 7.77 kcal/mol), bin 2 (4–5 A˚ with energy 3.77
kcal/mol), and bin 3 (5–5.5 A˚ with energy 5.61 kcal/mol)
according to the ﬂexible template structures, any of the three
distance bins can be chosen by the model, and the two Ca pos-
itions (xi, xk) are thus allowed to move within a range of 2.5 A˚.
Stage two: fold speciﬁcity
The second stage of the new framework provides a more
rigorous assessment of the speciﬁcity of the low energy
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sequences within the context of the ﬂexible template. One
approach for fold speciﬁcity uses the ASTRO-FOLD method
and performs ﬁrst-principles-based protein folding calcula-
tions to generate two sets of conformational ensembles: one
in which the protein is constrained to a region around the
backbone and a second in which the protein is allowed to
fold freely (72–78). This requires the use of the deterministic
global optimization approach, aBB (79–86). The relative
probability of speciﬁcity for the protein to assume the target
fold is then calculated from the RMSD and free energy of
these two ensembles based on the Boltzmann distribution.
For rigorous ensemble generation, this method requires that
a large number of freefolding calculations be performed,
which can be computationally demanding.
A new second-stage method has been developed to handle
larger proteins. This method for fold validation is outlined in
Fig. 1. First, a ﬂexible template is deﬁned based on the upper
and lower bounds on both the distances between a-carbons
and the f- and c-angles between residues. An ensemble of
hundreds of random structures is then generated (con-
formers) within the conﬁnes of the ﬂexible template using
the CYANA 2.1 software package for NMR structure
reﬁnement (63,64). CYANA 2.1 is then used to perform
annealing calculations that simulate a rapid heating of the
protein followed by a slow cooling in which high temper-
ature torsion dynamics and annealing torsion dynamics are
performed. Violations of van der Waals radii and of the
ﬂexible template are minimized, minimizing the energy of
the target structures. Hundreds of these structures are
generated within the conﬁnes of the ﬂexible template.
For each structure in the ensemble, local minimizations
are then performed by the TINKER (87) package as directed
by gradients in the fully atomistic force ﬁeld AMBER (62).
AMBER is then used to evaluate the potential energy of the
structure. These ensembles are generated for the native
sequence of the fold and for each candidate mutant sequence.
The speciﬁcity of each mutant sequence to the target fold is
then calculated relative to the native sequence using the
Boltzmann distribution from statistical mechanics. Both the
predicted energy of each conformer and its RMSD from
the template structure are used in this calculation.
ANALYSIS AND SELECTION OF RESULTS
A method similar to that used by Klepeis et al. (17) for
ensemble comparison in fold validation was employed to give
a relative ranking for speciﬁcity. First, the mean and standard
deviation of both RMSD and AMBER energies were found
for the native sequence. Upper bounds on both RMSD and
energy were then established; for RMSD, the upper bound
was selected as one and a half standard deviations above the
mean, and in the energy, the upper bound was selected as two
standard deviations from the mean. A structure is considered
to make a contribution to the ensemble only if its energy and
RMSD both fall under these upper bounds. This is illustrated
in Fig. 2.
To calculate the relative factor for speciﬁcity, we deﬁne the
set native as the set of all data points from the native sequence
that are below both upper bounds, and select the set of all data
points from the novel sequence that meet the same criterion.
The factor for speciﬁcity, fspeciﬁcity, is then calculated using
Boltzmann probabilities as shown in the equation
fspecificity ¼
+
i2novel
exp½bEi
+
i2native
exp½bEi; (8)
where b ¼ 1=kBT:
Backbone ﬂexibility at stage two
True protein backbone ﬂexibility is incorporated in stage two
by CYANA’s ability to select any continuous values for the
dihedral angles and Ca-Ca distances between preset boundsFIGURE 1 Workﬂow for the new method for fold speciﬁcity.
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when it does the simulated annealing calculations. The
bounds are input by the user to the program, and they can be
based on the observation about the ﬂexible design template(s).
The outgoing protein conformations can thus have any pos-
sible combination of continuous angle and distance values
between the bounds.
DE NOVO DESIGN OF HUMAN b-DEFENSIN-2
This section outlines the details of the de novo design of
human b-defensin-2 using the two-stage de novo protein
design framework aforementioned.
Design templates
Three different sets of design templates were used for the de
novo design of human b-defensin-2.
Single template structure from x-ray crystallography
This design template corresponds to chain A of the x-ray
crystal structure elucidated by Hoover et al. (60) (PDB code:
1FD3) at a resolution of 1.35 A˚ (Fig. 3). Human b-defensin-
2 possesses an octameric quaternary structure constituted by
eight identical chains: chain A, B, C, D, E, F, G, and H, each
of which has the natural sequence of GIGDPVTCLKS-
GAICHPVFCPRRYKQIGTCGLPGTKCCKKP (88). The
identical monomer units of hbD-2 are grouped into units
of four that are oriented in such a way that their N-termini are
in the core of the octamer. The core is sealed off from solvent
by hydrogen bonds between Gly1, Gly3, Asp4, and Thr7. The
overall tertiary structure is maintained by a mix of hydro-
phobic and hydrogen-bonding interactions between the
residues Gly1, Asp4, Thr7, Lys10, Gly31, Leu32, Pro33, and
Lys39. Among the eight identical chains, only chain A was
used for the de novo design.
The surface of hbD-2 is mostly amphiphilic. Like other
human b-defensins, hbD-2 has an N-terminus a-helix
located at Pro5-Lys10 that is held against the b-sheet by an
S-S bond between Cys8 and Cys37. Two other S-S bonds that
stabilize the b-sheet are located at Cys15-Cys30 and Cys20-
Cys38. The b-sheet is made up of three anti-parallel b-strands
held together by hydrophobic interactions. The structural
properties of hbD-2 are summarized in Table 1.
Flexible templates from molecular dynamics simulations with
Generalized Born implicit solvation model
In an effort to generate a ﬂexible design template for human
b-defensin-2, molecular dynamics (MD) simulations were
employed to capture different structures of the peptide along
the MD trajectory. MD simulations were performed using
FIGURE 2 Illustration of upper bounds on RMSD and
AMBER energy. Lines indicate upper bounds. Data points
in the shaded regions are not considered in further
calculations.
FIGURE 3 Structure of human b-defensin-2 (chain A) as elucidated by
Hoover et al. (60). Its secondary structure consists of a b-sheet made up of
three b-strands and an a-helix.
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the program CHARMM (89) version 31b1, with implemen-
tation of the Generalized Born (GB) implicit solvent model
(90). The CHARMM19 force ﬁeld was employed with the
GBORn model. The dielectric constant was set to 1.0 for the
interior of the protein and 80.0 for the solvent. All non-
bonded interactions were computed without cutoffs. The
SHAKE algorithm (91) was used to ﬁx the length of covalent
bonds of hydrogen atoms. The time step was set to 2 fs.
Monomer A of the crystal structure 1FD3 was used. The
structure was ﬁrst energy-minimized for 300 steps, using the
adopted-basis Newton-Raphson (ABNR) method. Then,
the system was subjected to 5 ps of constant volume molec-
ular dynamics, during which the temperature was raised from
0 K to 300 K with velocity rescaled every 0.1 ps. At 300 K,
30-ps equilibrium phase was performed, with velocity re-
scaled every 0.1 ps, during the ﬁrst 10 picoseconds. In the
middle 10 picoseconds, velocity was rescaled only if the
temperature of the system deviated more than 5 K from
300 K. During the last 10 picoseconds, energy and tempera-
ture were stable, and no velocity rescaling was necessary.
After the equilibration, a 10-ns trajectory of NVT MD at 300
K was generated. Coordinate sets were sampled every 10 ps
to generate 1000 snapshots of structures. A total of 10 struc-
tures with 1-ns increment were extracted from the MD tra-
jectory to constitute the set of ﬂexible templates, which is
shown in Fig. 4.
Flexible templates from molecular dynamics simulations with
explicit water molecules
Here MD simulations were done in a more computationally
demanding manner by the explicit treatment of water
molecules. The program CHARMM (89) version 31b1,
with the CHARMM27 force ﬁeld, was used for the MD
simulation with explicit solvation. Monomer A of the crystal
structure 1FD3 was used. The protein was immersed in a
50 3 50 3 50 A˚3 cubic box of TIP3P water models. Water
molecules were deleted when their oxygen atoms were
within 2.8 A˚ of any heavy atom of the protein. One sodium
ion and seven chloride ions were added to represent ;100
mM salt concentration and to neutralize the overall system.
The dielectric constant was set to 1.0. Nonbonded interaction
cutoff of 12.0 A˚ was used, with a force-switching function
for electrostatic interactions and shifting function for van der
Waals interactions between 9 and 12 A˚. First, the protein was
minimized using 500 steps of the ABNR method with water
molecules being held ﬁxed. Subsequently, the entire system
was relaxed without any constraints with 500 steps of ABNR
minimization. The ﬁnal system comprises 11,328 atoms in-
cluding water molecules, protein (610 atoms), and ions. Dur-
ing the equilibration and production molecular dynamics, the
protein was restrained to the center of the water box. The
system was ﬁrst heated from 0 K to 300 K with 30 ps of
molecular dynamics, during which velocities were scaled
every 1 ps and was allowed to ﬂuctuate within 5 K of the
target temperature. After heating, the system was equilibrated
at 300 K for an additional 100 ps. After the equilibration, a 2-
ns MD trajectory was generated at 300 K. Coordinate sets
were sampled every 10 ps to generate 200 snapshots of struc-
tures. A total of 10 structures with 0.2 ns increment were
extracted from the MD trajectory to constitute the set of
ﬂexible templates, which is shown in Fig. 5. Alignment of
the three different sets of design templates (Fig. 6) indicates
ﬂexibility and high structural similarity among them.
The de novo design
Stage one: in silico sequence selection
Models. Different models were employed for sequence se-
lection, depending on the nature of the design template(s).
The basic model for single structure (Eq. 1) sufﬁces for the
single crystal structure by Hoover et al. (60). For the other
FIGURE 4 Overlay of the 10 structures of human b-defensin-2 used for
the ﬂexible design template from MD simulations with the GB implicit
solvation model. The structures are snapshots with 1-ns increment.
TABLE 1 Structural features of human b-defensin-2
Structural features Positions
b-strands 14–16
25–28
36–39
a-helix 5–10
8–37
S-S bonds 15–30
20–38
16–19
b-turns 21–24
32–35
Hairpins 25–29
Bulges 27, 28, 37
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two ﬂexible design templates generated from MD simula-
tions which have multiple structures, both the weighted aver-
age force ﬁeld formulation (Eq. 3) and the binary distance
bin variable formulation (Eq. 7) were utilized for sequence
selection.
Force ﬁelds. The high resolution Ca-Ca force ﬁeld (69) was
employed for sequence selection based on the design
template from x-ray crystallography, while the high resolu-
tion centroid-centroid force ﬁeld (70) was used for the two
sets of templates from MD simulations.
Number of sequence solutions. One-hundred sequences
were generated for the crystal structure template in the ﬁrst
stage, and they were ranked by their fold speciﬁcities based
on the full-atomistic force ﬁeld AMBER in the second stage.
For the ﬂexible templates from MD simulations, ;1000
sequences and ;500 sequences were solved using the
weighted average model (Eq. 3) and distance bin model
(Eq. 7), correspondingly.
Mutation set. SASA patterning was applied to restrict the
sequence search space for the de novo design of hbD-2. The
41 positions in hbD-2 are classiﬁed into the core, surface,
and intermediate categories which determine the mutation
set for each position. The native residue for each position is
also included in its mutation set. Proline is excluded from the
list for surface and intermediate positions to avoid unnec-
essary rigidity imposed on the backbone, except when it is
the native residue for the position. The mutation set for
human b-defensin-2 is tabulated in Table 2. This SASA
patterning strategy aims at conserving the natural amphiphi-
FIGURE 6 Structural alignment of the crystal structure of human
b-defensin-2 (chain A) by Hoover et al. (60) (rainbow color), the 5-ns
MD-GB structure (light gray), and the 1-ns explicit MD structure (dark gray).
FIGURE 5 Overlay of the 10 structures of human b-defensin-2 for the
ﬂexible design template fromMD simulations with explicit water molecules.
The structures are snapshots with 0.2-ns increment.
TABLE 2 Mutation set of human b-defensin-2 given by
SASA patterning
Position
Native
residue
Side-chain
accessibility
Position
type
Varied
position?
Allowed
mutations
1 G 139.6% surface O R,N,D,Q,E,G,H,K,S,T
2 I 20.7% intermediate O all except C and P
3 G 69.0% surface O R,N,D,Q,E,G,H,K,S,T
4 D 52.5% surface O R,N,D,Q,E,G,H,K,S,T
5 P 52.1% surface O R,N,D,Q,E,G,H,K,P,S,T
6 V 99.9% surface O R,N,D,Q,E,G,H,K,S,T,V
7 T 54.9% surface O R,N,D,Q,E,G,H,K,S,T
8 C 0.0% buried 3 none
9 L 64.5% surface O R,N,D,Q,E,G,H,K,S,T,L
10 K 94.2% surface O R,N,D,Q,E,G,H,K,S,T
11 S 52.2% surface O R,N,D,Q,E,G,H,K,S,T
12 G 97.3% surface O R,N,D,Q,E,G,H,K,S,T
13 A 1.8% buried O A,I,L,M,F,Y,W,V
14 I 49.6% intermediate O all except C and P
15 C 18.9% buried 3 none
16 H 24.9% intermediate O all except C and P
17 P 66.4% surface O R,N,D,Q,E,G,H,K,S,T,P
18 V 79.0% surface O R,N,D,Q,E,G,H,K,S,T,V
19 F 69.1% surface O R,N,D,Q,E,G,H,K,S,T,F
20 C 10.7% buried 3 none
21 P 32.0% intermediate O all except C
22 R 92.2% surface O R,N,D,Q,E,G,H,K,S,T
23 R 84.6% surface O R,N,D,Q,E,G,H,K,S,T
24 Y 24.7% intermediate O all except C and P
25 K 82.3% surface O R,N,D,Q,E,G,H,K,S,T
26 Q 46.7% intermediate O all except C and P
27 I 42.1% intermediate O all except C and P
28 G 45.8% intermediate O all except C and P
29 T 54.1% surface O R,N,D,Q,E,G,H,K,S,T
30 C 2.6% buried 3 none
31 G 60.3% surface O R,N,D,Q,E,G,H,K,S,T
32 L 87.1% surface O R,N,D,Q,E,G,H,K,S,T,L
33 P 86.1% surface O R,N,D,Q,E,G,H,K,S,T,P
34 G 96.5% surface O R,N,D,Q,E,G,H,K,S,T
35 T 13.9% buried O A,I,L,M,F,Y,W,V,T
36 K 33.2% intermediate O all except C and P
37 C 0.0% buried 3 none
38 C 0.0% buried 3 none
39 K 45.8% intermediate O all except C and P
40 K 61.2% surface O R,N,D,Q,E,G,H,K,S,T
41 P 58.5% surface O R,N,D,Q,E,G,H,K,S,T,P
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licity of hbD-2, which is considered important for the
antimicrobial activity of the peptide (9). Complexity of the
problem amounts to 6.40 3 1037.
Biological constraints. Homology search was executed to
determine what fundamental properties of hbD-2 have been
highly conserved in evolution. These conserved fundamental
properties are maintained in the de novo designed protein as
they can contribute signiﬁcantly to the protein structure and
function (92,93).
Such a homology search on hbD-2 was performed using a
position-speciﬁc iterative basic local alignment search tool
(PSI-BLAST 2.0) (l). A total of 96 human b-defensin
homologs were identiﬁed. The conserved properties about
their charges and amino acid content are tabulated in Tables
3 and 4, respectively, and they correspond to the upper and
lower bounds on the charges and amino-acid composition.
The upper bound and lower bound on the amino-acid con-
tent were set equal to the maximum and minimum occur-
rences found in the hbD-2 homologs, respectively, except
for cysteine, glycine, and tryptophan. The number of cyste-
ines was ﬁxed to six in view of the three disulﬁde bonds in
hbD-2. The number of glycines was limited to be#6, which
is its occurrence in the native sequence, while tryptophan
content was allowed to have an upper bound of two instead
of one as suggested by homology search, so that the overall
hydrophobicity can be enhanced for higher molecular stability.
The conserved charge characteristics of hbD-2 homologs
were converted to the constraints below and added to the
sequence selection models:
0#+
i
yArgi 1+
i
yLysi +
i
yAspi +
i
yGlui #3"5# i#10
5#+
i
y
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i
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i #2"i
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i
y
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i #9"i: (9)
These linear constraints would restrict the charges on any
sequence solution generated from stage one to be within the
bounds stated in Table 3.
Residue frequencies on the whole sequence were also con-
strained to be between the maximum and minimum occur-
rences found in the hbD-2 homologs, by means of the
following equations:
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Lastly, b-strands were restricted to have at least two hydro-
phobic residues to ensure enough hydrophobic interaction
between b-strands for stability purpose. The requisite con-
straints are
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TABLE 3 Charge frequencies of homologs of
human b-defensin-2
Lower bound Upper bound
Net charge on a-helix 0 13
Total positive charges 5 10
Total negative charges 0 2
Total net charges 14 19
TABLE 4 Occurrence of each amino acid in human
b-defensin-2 homologs; residues with asterisks do not follow
the maximum and minimum occurrences found in the
sequences from the homology search (refer to the text for
the actual constraints imposed)
Amino acid Lower bound Upper bound
Ala 0 3
Arg 1 9
Asn 0 6
Asp 0 2
Cys* 4 7
Gln 0 3
Glu 0 3
Gly* 3 7
His 0 4
Ile 0 6
Leu 0 4
Lys 0 7
Met 0 3
Phe 0 4
Pro 0 5
Ser 0 6
Thr 0 4
Trpy 0 1
Tyr 0 4
Val 0 6
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Note that no constraint was imposed on the third b-strand
that already has two nonvaried cysteines, which are hydro-
phobic.
Number of mutations. In the sequence selection for the
design template from x-ray crystallography, the number of
mutations was set to be not more than 10 by the constraint
below:
+
n
i¼1
+
mi
j¼1;j 6¼native residues
y
j
i#10: (12)
For the other two sets of ﬂexible templates, the maximum
number of mutations was either set to 10, or unlimited. The
latter case corresponds to a full-sequence design of human
b-defensin-2, since all positions, except for the six native
cysteines, were varied.
Stage two: fold speciﬁcity
In calculating the fold speciﬁcities using the AMBER force
ﬁeld, the angle and distance bounds input to the CYANA 2.1
package were610 around the template and610% of those
in the template, respectively, for the sequences from the
single crystal structure template. For the sequences from the
ﬂexible templates from MD simulations, the bounds were set
to be the maximum and minimum as observed from all
template structures. Five-hundred low energy conformations
were generated for each sequence by the simulated annealing
algorithm in CYANA and their energies were minimized
further by the TINKER program. Finally, the fold speciﬁcity
for each sequence was computed using formula (8), and the
sequences were then ranked according to their speciﬁcities.
RESULTS AND DISCUSSION
The top sequences ranked by their fold speciﬁcities for the
design template from x-ray crystallography, MD simulations
with generalized Born implicit solvent, and MD simulations
with explicit water molecules are listed in the Supplementary
Material in Table S1, Tables S2–S5, and Tables S6–S9,
respectively.
Results based on the single template structure
from x-ray crystallography
As shown in Table S1 (see Supplementary Material), the
high resolution Ca-Ca force ﬁeld suggests the mutations of
G3T, D4R, I14V, H16V, P17H, R22N, Q26F, G28F,
K36(V/F), K39(A/F/Y), and K40N, when the number of mu-
tations is limited to be not more than 10.
Results based on the ﬂexible templates from
molecular dynamics simulations with Generalized
Born implicit solvation model
In this run, when an upper bound of 10 is imposed on the
number of mutations, the weighted average sequence selec-
tion model driven by the centroid-centroid force ﬁeld sug-
gests the mutations of P5R, H16(F/I), P17(Q/N/R), P21I,
Q26(I/L/Y), G28L, G31(K/Q), G34R, T35W, K36W, and
K39(L/Y) (see Table S2 in Supplementary Material); the
binary distance bin sequence selection model with the same
force ﬁeld prefers P5R, G12(H/D), A13F, H16(I/F/W),
P17(R/N), P21I, Q26(L/I), G28(L/Y), G31(K/Q), G34R,
T35W, K36(W/Y), and K39Y (see Table S3 in Supplemen-
tary Material).
For full-sequence design, the following predictions given
by the weighted average model yield the highest fold
speciﬁcity: G1D, I2(F/M), G3H, D4(E/G), P5(K/Q), T7(R/
H/K), K10(G/H), S11(K/H), G12(N/H), A13(I/F), H16I,
P17R, P21I, R22(T/H/Q/K), R23(G/Q), Y24I, K25(G/R/N),
Q26(I/L), I27(L/Y), G28(Y/L), T29K, G31(K/Q), P33E,
G34R, T35W, K36W, K39(L/Y), K40(N/Q/R), and P41(Q/
T) (see Table S4 in Supplementary Material); the corre-
sponding predictions made by the distance bin model are:
I2M, D4(N/K), P5N, T7(N/G), K10G, S11(R/E/D), G12(D/
H/K), A13F, I14F, H16W, P17(R/K), P21F, R22H, R23H,
Y24I, K25H, Q26I, I27Y, G28Y, T29(N/Q/E/K), G31Q,
TABLE 5 For either up to 10 mutations or full-sequence design, common mutations suggested by both the weighted average model
(Eq. 3) and the binary distance bin model (Eq. 7) that are found in both sets of templates are underlined; those underlined mutations
that are found in both cases of #10 mutations and full-sequence design are added an asterisk each
Templates from MD simulations with GB implicit solvent Templates from MD simulations with explicit water molecules
Up to 10 mutations P5R H16(F/I) P17(N/R) H16(F/I) P21(I/Y) Q26(I/F)
P21I Q26(I/L) G28L G28L G34R* T35W
G31(K/Q) G34R* T35W K36W K39Y*
K36W K39Y*
I2M K10G G12H G1D I2F D4K
A13F P17R R22H T7N K10G A13I
Full sequence design Y24I Q26I I27Y I14L P17R P21I
G28Y T29K G31Q R22Q R23G Y24L
G34R* T35W K39Y* K25R Q26F I27Y
G28Y G34R* K36W
K39Y* K40R P41(G/Q)
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P33Q, G34R, T35W, K36Y, K39Y, and P41(K/N) (see
Table S5 in Supplementary Material).
Results based on the ﬂexible templates from
molecular dynamics simulations with explicit
water molecules
For this set of templates, when the number of mutations is
restricted to be #10, the weighted average model suggests
the mutations of G3D, P5(R/N), H16(I/F/Y), P21(I/Y/V),
Q26(I/F), G28L, G31(Q/N), G34R, T35W, K36W, and
K39(L/Y) (see Table S6 in Supplementary Material); the
distance bin model selects G12(D/E), A13F, H16(L/F/I),
P21(Y/I), Q26(I/F/L), G28(L/Y), G34R, T35W, K36W, and
K39Y (see Table S7 in Supplementary Material).
In the case of full-sequence design, the weighted average
model suggests the following mutations: G1(D/E), I2F,
G3D, D4K, P5N, T7N, K10G, S11H, G12H, A13(Y/I),
I14L, H16(Y/I/F), P17R, P21I, R22(G/Q), R23G, Y24L,
K25(R/G), Q26F, I27Y, G28Y, T29K, G31N, P33N, G34R,
T35W, K36W, K39(Y/I), K40R, and P41(G/T/Q) (see Table
S8 in Supplementary Material); the corresponding mutations
selected by the distance bin model are: G1D, I2F, G3H,
D4K, P5H, T7(K/N), K10G, S11(N/G), G12(K/E), A13(F/I),
I14L, H16W, P17R, P21I, R22(N/Q/T), R23G, Y24(I/L),
K25R, Q26F, I27Y, G28Y, T29H, G31H, P33R, G34R,
T35Y, K36W, K39Y, K40(N/R/Q), and P41(G/Q) (see
Table S9 in Supplementary Material).
Similarities and differences between results
based on the two sets of ﬂexible templates from
molecular dynamics simulations
While the results from the single x-ray crystal structure are
based on the high resolution Ca-Ca force ﬁeld and should
stand alone by themselves, results based on the two sets of
ﬂexible templates from MD simulations are all produced
using the centroid-centroid force ﬁeld. In the latter case, high
TABLE 6 Different mutations suggested by the weighted average model (Eq. 3) and the binary distance bin model (Eq. 7) in each of
the cases of #10 mutations and full-sequence design and in each of the two sets of ﬂexible templates based on MD simulations
Templates from MD simulations with GB implicit solvent Templates from MD simulations with explicit water molecules
Up to 10 mutations Weighted average model Weighted average model
P17Q K39L G3D P5(R/N) H16Y
P21V G31(Q/N) K39L
Distance bin model Distance bin model
G12(H/D) A13F H16W G12(D/E) A13F H16L
Q26Y G28Y K36Y Q26L G28Y
Full sequence design Weighted average model Weighted average model:
G1D I2F G3H G1E G3D P5N
D4(E/G) P5(K/Q) T7(R/H/K) S11H G12H A13Y
K10H S11(K/H) G12N H16(Y/I/F) R22G K25G
A13I H16I P21I T29K G31N P33N
R22(T/Q/K) R23(G/Q) K25(G/R/N) T35W K39I P41T
Q26L I27L G28L
G31K P33E K36W
K39L P41(Q/T)
Distance bin model: Distance bin model:
D4(N/K) P5N T7(N/G) G3H P5H T7K
S11(R/E/D) G12(D/K) I14F S11(N/G) G12(K/E) A13F
H16W P17K P21F H16W R22(N/T) Y24I
R23H K25H T29(N/Q/E) T29H G31H P33R
P33Q K36Y P41(K/N) T35Y K40(N/Q)
TABLE 7 For either the weighted average model (Eq. 3) or the binary distance bin model (Eq. 7) for sequence selection, common
mutations in the cases of #10 mutations and full-sequence design that are found in both sets of templates are underlined; those
underlined mutations that are found in both the weighted average model and the binary distance bin model are added an asterisk each
Templates from MD simulations with GB implicit solvent Templates from MD simulations with explicit water molecules
Weighted average model H16I P17R P21I G3D P5N H16(I/F/Y)
Q26(I/L) G28L G31(K/Q) P21I Q26F G31N
G34R* T35W K36W G34R* T35W K36W
K39(Y*/L) K39Y*
Binary distance bin model G12(H/D) A13F H16W G12E A13F P21I
P17R Q26I G28Y Q26F G28Y G34R*
G31Q G34R* K36Y K36W K39Y*
K39Y*
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level of similarity is observed between the weighted average
model predictions and the distance bin model predictions, as
well as those for up to 10 mutations and those corresponding
to the full-sequence design.
Weighted average model versus binary distance
bin model
In each of the cases of up to 10 mutations and full-sequence
design and for each of the two ﬂexible templates from MD
simulations, the common mutations predicted by both the
weighted average model and the binary distance bin model
are tabulated in Table 5. Those common mutations that are
found in both sets of ﬂexible templates are underlined. It
should be noted that G34R and K39Y are seen in all cases.
The high level of similarity clearly suggests that the
weighted average model can be used as a good approxima-
tion for the distance bin model, which is more computation-
ally demanding, in de novo designs where the problem
complexities are high.
The different mutations from the two models in each of the
cases of up to 10 mutations and full-sequence design for each
of the two ﬂexible templates from MD simulations are listed
in Table 6.
Up to 10 mutations versus full-sequence design
Here we identify the mutations in the case of up to 10 mu-
tations that are also found in the full-sequence design case,
and we perform this for the weighted average formulation
FIGURE 7 Clustering and optimal reordering of the 4266
sequences predicted from all sequence selection models with
the ﬂexible templates. Dotted lines indicate cluster bound-
aries. Different amino acids at the 41 positions are illustrated
with different colors.
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and the distance bin formulation for each of the two template
sets. The results can be found in Table 7. The common mu-
tations that are the same for both sets of ﬂexible templates are
underlined. In each of the four cases shown, the number of
common mutations is close to 10, indicating that predictions
for up to 10 mutations are usually also found in the full-
sequence design.
Clustering of predicted sequences
We performed sequence clustering to assess the similarity
among the sequences predicted from each of the models
using the ﬂexible templates. The substitution matrix PAM70
was used to quantify the distance between sequences because
it is recommended for query lengths between 35 and 50 amino
acids (94,95). The diagonal of this matrix was modiﬁed so
that exact matches between amino-acid residues had equiv-
alent scores. Combining the sequences predicted from all the
models results in 4266 protein sequences with 41 amino
acids in each. We determined the best rearrangement of the
protein sequences by minimizing the sum of the overall
residue-pair distances for each position using an optimal
reordering method (unpublished data). The results for the
reordered proteins are presented in Fig. 7. Cluster boundaries
are subsequently identiﬁed from the reordered proteins using
the following method. In the ﬁnal ordering, each sequence is
assigned to its own cluster. We examined the average dis-
tance between each cluster to its neighboring clusters in the
ﬁnal ordering and then merged the two clusters that are of
minimum distance apart. This is done iteratively until the
maximum number of clusters (to be speciﬁed by the user) is
reached.
As shown in the ﬁgure, the largest clusters correspond to
the following sequences: G1-I2-G3-D4-(P/R/K/N)5-V6-T7-C8-
L9-K10-S11-G12-A13-I14-C15-(F/I/L)16-(P/R)17-V18-F19-C20-(I/
Y)21-R22-R23-Y24-K25-(I/L/V/F)26-I27-(I/L/Y)28-T29-C30-(K/
G)31-L32-P33-(G/R)34-W35-W36-C37-C38-(L/Y)39-K40-P41. This
is obviously contributed from the runs with not more than 10
mutations. Within these clusters, results from the four differ-
ent sets using the weighted average model and the distance
bin model with either the ﬂexible templates from MD simu-
lations with GB implicit solvent or the templates from MD
simulations with explicit water molecules were observed
to be interspersed, suggesting a high level of conservation
among these sequences.
In addition, we compared our predictions to 90 human
b-defensin homologs obtained by running the sequence
alignment tool of PSI-BLAST, which was created by the
National Center for Biotechnology Information of the
National Institute of Health, with the default threshold of
0.005 for the position conservation score. Residues at each of
the 41 positions found among these homologs are listed in
Table 8. To note, except for positions 28, 35, 36, and 39,
residues in the major clusters shown above are found in these
homologs. This reveals that while our predictions are
natural-looking to a large extent, some positions are diverse
enough for favorable potential energy contributions.
CONCLUSIONS
A new de novo protein design methodology, which incor-
porates true backbone ﬂexibility (71) as deﬁned by bounded
continuous values of dihedral angles and Ca-Ca distances, is
presented. Its application on full-sequence design of small
proteins is demonstrated with the study of redesigning
hbD-2, which is a 41-residue cationic peptide central to the
defense of innate immune system against microbial attack.
This study about hbD-2 also shows that the framework can
serve as a useful predictive tool for screening peptide/protein
drugs and speeding up their development process.
TABLE 8 Residues at each of the 41 positions among the
human b-defensin homologs obtained by using PSI-BLAST;
those with an asterisk agree with the major clusters of all our
predicted sequences
Position Residues
1 G*
2 I*,A,V
3 G*,S,M,R,N,I,K,E,T
4 D*,N,G,S,T,E
5 P*,S,H,R*,F,Y,T
6 V*,I,L,R,Q,F,A,K
7 T*,S,K,Q,A
8 C*,Y
9 L*,I,A,S,V,R,Y,H,G,M,W,F,C
10 K*,R,T,L,G,I,Q,W,M,S,E,A,V
11 S*,N,K,H,Y,I,R,A
12 G*,R,K,S,M,N,I
13 A*,G,N,D,R
14 I*,V,F,R,T,Y,A,S
15 C*
16 H,Y,I*,V,M,W,L*,A,F*,Q,R
17 P*,R*,S,G,L,N,A,Y,T,F
18 V*,R,I,P,G,S,A,D,T,F,N,L,Y,K,M
19 F*,S,G,K,R,W,C,L,Y,Q,E,N,D,T
20 C*,I
21 P,L,A,T,I*,G,S,K,R,N
22 R*,G,P,V,T,H,L,Y,W
23 R*,S,G,N,K,P,H,A,T,F,L
24 Y*,M,S,F,L,T,R,H,Q,I,E
25 K*,R,E,I,D,L,Y,N,T
26 Q,E,R,S,V*,L*
27 I*,V,N,L,G
28 G
29 T*,V,N,R,S,I,H
30 C*
31 G*,S,V,L,F,H,R,I,Y
32 L*,V,G,M,T,H,A,F,S,R,E,P,D,K
33 P*,S,R,G,A,F,T,Y,K,L
34 G*,V,A,Q,P,R*,S,K,I,F,L
35 T,I,S,V,Q,L,F,G,A,R
36 K,R,P,N
37 C*
38 C*
39 K,R,Q,H
40 K*,R
41 P*
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